Notable Labs

Notable Labs Treasury Stock

The Treasury Stock of Notable Labs (NTBLQ) as of Nov 8, 2026 is 110,000.00 USD. In the previous year, Treasury Stock was 40,000.00 USD — a change of 175.00% (higher).

Treasury Stock

110,000.00USD

YoY

175.00%

Last updated:

Treasury Stock of Notable Labs is 2023 110,000.00 USD. Treasury Stock of Notable Labs was 2022 40,000.00 USD. It decreases by 175.00% higher compared to the previous year.

The Notable Labs Treasury Stock history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Treasury Stock
Date
Treasury Stock
Jan 1, 2014
40,000.00 USD
Jan 1, 2015
50,000.00 USD
Jan 1, 2016
40,000.00 USD
Jan 1, 2017
20,000.00 USD
Jan 1, 2018
40,000.00 USD
Jan 1, 2023
110,000.00 USD
The Notable Labs Treasury Stock history
YEARTreasury StockYoY
110,000.00USD+175.00%
40,000.00USD+100.00%
20,000.00USD-50.00%
40,000.00USD-20.00%
50,000.00USD+25.00%
40,000.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Notable Labs Stock analysis

What does Notable Labs do? Notable Labs Ltd, formerly Vascular Biogenics Ltd, is an Israel-based clinical-stage biopharmaceutical company developing targeted medicines for cancer and immune-inflammatory diseases. The company leverages two platform technologies: Vascular Targeting System (VTS), a gene-based approach targeting newly formed blood vessels, and Monocyte Targeting Technology (MTT), an antibody-based method inhibiting monocyte migration. Its product candidates aim to improve patient outcomes by overcoming limitations of current treatments. The firm's pipeline focuses on difficult-to-treat conditions, with VTS and MTT serving as the core technologies for developing therapeutics. VTS targets cancer by focusing on blood vessel formation, while MTT addresses immune-inflammatory diseases through monocyte migration control. These technologies enable the creation of next-generation medicines that address unmet medical needs. Notable Labs Ltd sells its product candidates to pharmaceutical companies and healthcare providers for further development and clinical trials. The primary buyers are biopharmaceutical firms seeking innovative therapies, particularly those targeting cancer and immune-inflammatory conditions. The company's revenue model relies on licensing agreements and partnerships with these industry players to advance its pipeline. Notable Labs is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Notable Labs stock

Treasury Stock of Notable Labs is 110,000.00 USD in 2023.

Treasury Stock of Notable Labs changed from 40,000.00 USD to 110,000.00 USD, representing a 175.00% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Treasury Stock Notable Labs since 2006 – with annual values, charts, and detailed analysis.

Treasury stock represents shares that were repurchased by the company. It reduces shareholders' equity and outstanding share count.

Treasury Stock's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Treasury Stock's Notable Labs historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Notable Labs

All Key Metrics — Notable Labs